Article Text

Download PDFPDF
Repeated infusions of infliximab, a chimeric anti-TNFα monoclonal antibody, in patients with active spondyloarthropathy: one year follow up
  1. E Kruithof,
  2. F Van den Bosch,
  3. D Baeten,
  4. A Herssens,
  5. F De Keyser,
  6. H Mielants,
  7. E M Veys
  1. Department of Rheumatology, Ghent University Hospital, Belgium
  1. Correspondence to:
    Dr E Kruithof, Department of Rheumatology, OK12IB, Ghent University Hospital, De Pintelaan 185, 9000 Gent, Belgium;


Background: In a pilot study, the anti-tumour necrosis factor α monoclonal antibody, infliximab, induced a rapid and significant improvement in global, peripheral, and axial disease manifestations of patients with active spondyloarthropathy.

Objective: To determine whether repeated infusions of infliximab would effectively and safely maintain the observed effect.

Methods: Safety and efficacy of a maintenance regimen (5 mg/kg infliximab every 14 weeks) was evaluated using the measurements reported in the pilot study. Of the 21 patients, 19 completed the one year follow up for efficacy; two patients changed to another dosing regimen after week 12 owing to partial lack of efficacy. However, they are still being followed up for safety analysis.

Results: After each re-treatment a sustained significant decrease of all disease manifestations was observed. Before re-treatment, symptoms recurred in 3/19 (16%) at week 20, in 13/19 (68%) at week 34, and in 15/19 (79%) at week 48. No withdrawals due to adverse events occurred. Twelve minor infectious episodes were observed. Twelve patients (57%) developed antinuclear antibodies; in four of them (19%) anti-dsDNA antibodies were detected. However, no lupus-like symptoms occurred.

Conclusion: In this open study of infliximab in patients with active spondyloarthropathy, the significant improvement of all disease manifestations was maintained over a one year follow up period without major adverse events. Although recurrence of symptoms was noted in a rising number of patients before each re-treatment, no loss of efficacy was observed after re-treatment.

  • spondyloarthropathy
  • ankylosing spondylitis
  • psoriatic arthritis
  • anti-TNFα
  • ANA, antinuclear antibodies
  • AS, ankylosing spondylitis
  • CRP, C reactive protein
  • ESR, erythrocyte sedimentation rate
  • PsA, psoriatic arthritis
  • RA, rheumatoid arthritis
  • SpA, spondyloarthropathies
  • TNFα, tumour necrosis factor α
  • uSpA, undifferentiated spondyloarthropathy
  • VAS, visual analogue scale

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.